Join the Class Action Against MacroGenics: Claim Your Share
Join the Class Action Against MacroGenics, Inc.
Levi & Korsinsky, LLP is notifying investors in MacroGenics, Inc. (NASDAQ: MGNX) about an important class action securities lawsuit. This action aims to recover losses for investors adversely affected by alleged securities fraud. The timeline for the class period stretches from March 7, 2024, to May 9, 2024.
Understanding the Class Action Lawsuit
The lawsuit is focused on losses incurred by those who invested in MacroGenics during this specific period. The key issue centers around misrepresentations related to safety data from the company's TAMARACK Phase 2 study regarding vobramitamab duocarmazine. After disclosures regarding the drug's dangers, MGNX's stock plummeted 77.4%, corresponding to a loss of $11.36 per share.
What Investors Need to Know
Filing for Lead Plaintiff Status
If you experienced a loss in MacroGenics stocks during this timeframe, you have until September 24, 2024, to apply for lead plaintiff status. It's essential to understand that serving as a lead plaintiff is not a requirement to share in any recovery from the lawsuit.
No Financial Risk
Participating in the class action poses no financial burden to investors. If you are recognized as a class member, you may be entitled to compensation without needing to pay any fees or other costs upfront. This presents a significant opportunity for investors looking to reclaim losses.
Why Choose Levi & Korsinsky?
With a legacy of over 20 years, Levi & Korsinsky has recovered hundreds of millions of dollars for disgruntled shareholders across the United States. Their team is well-equipped to manage complex securities litigation, boasting over 70 dedicated professionals focused on supporting clients through challenging times. For seven consecutive years, they have been recognized as one of the top firms in securities litigation by ISS Securities Class Action Services.
Investor Outreach Details
If you are an investor seeking more information, you can contact Joseph E. Levi, Esq. at (212) 363-7500. Alternatively, feel free to reach out for further guidance regarding your options and potential benefits in participating in this class action.
Frequently Asked Questions
What is the deadline to join the class action against MacroGenics?
The deadline for investors to join the class action is September 24, 2024.
Who can join the class action lawsuit?
Any investor who suffered losses during the class period between March 7, 2024, and May 9, 2024, can join the lawsuit.
Are there any fees to participate?
No, class members may be entitled to compensation without any out-of-pocket costs or fees.
What does it mean to be a lead plaintiff?
Being a lead plaintiff means you would represent the class in the lawsuit, but it is not necessary to serve in this role to benefit from potential recoveries.
Why is Levi & Korsinsky a good choice for representation?
Levi & Korsinsky has a proven track record of recovering significant amounts for investors and is recognized among the top firms in securities litigation.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.